Pure Global
NCT04868981

Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets

To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Multiple-administration Study in Patients With Chronic Hepatitis B
Fujian Cosunter Pharmaceutical Co. Ltd·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis B
Drug/Device/Intervention
GST-HG141 tablets
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fujian Cosunter Pharmaceutical Co. Ltd
Location
Changchun, China
Timeline & enrollment
Phase
Phase 1
Start date
May 31, 2021
End date
Mar 14, 2022
Enrollment
30 participants
Primary outcome

Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities.,Cmax of GST-HG141,AUC of GST-HG141,t1/2 of GST-HG141,Cl/F of GST-HG141

Summary

To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in
 Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose,
 Multiple-administration Study in Patients With Chronic Hepatitis B (CHB)

ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04868981
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04868981 through Pure Global AI's free database. This Phase 1 trial is sponsored by Fujian Cosunter Pharmaceutical Co. Ltd and is currently Completed. The study focuses on Hepatitis B. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.